Metabolic Benefits Retatrutide significantly improves insulin sensitivity, blood sugar, cholesterol, and liver fat. For people with type 2 diabetes, fatty liver disease, or metabolic syndrome, this triple agonist shows serious potential.

Is Retatrutide an injection? Yes, Retatrutide is given as a weekly injection. Clinical trials have shown an average weight loss of up to 24.2% after 48 weeks. It is also being studied for treating type 2 diabetes, where it has significantly improved blood sugar control and led to noticeable weight loss.

As interest in Retatrutide continues to grow within the research and wellness community, many are asking the same question,“When will Retatrutide be available?” While Retatrutide is currently being studied in clinical and research environments, it is not approved for consumer or medical use. However, researchers and laboratories can now access Retatrutide formulations exclusively through Alluvi […]

Retatrutide and tirzepatide are different drugs with different chemical compositions. While retatrutide mimics three hormones to support weight loss, tirzepatide mimics two. Still, weight loss outcomes on retatrutide and tirzepatide are similar based on the research conducted so far. Tirzepatide supports an average weight loss of around 25% after 52 weeks. On retatrutide, it’s around […]

In 2023, a randomised controlled trial on 338 participants showed that retatrutide supported an average weight loss of 24% after 48 weeks. If you weighed 100 kg, this would be a weight loss of 24kg. Additionally, 100% of participants on the higher doses of the drug lost more than 5% of their weight, 93% lost more than […]

Retatrutide is a triple-action weight-loss injection manufactured by Eli Lilly. It’s undergoing later-stage human clinical trials to determine its effectiveness across a broader population. Retatrutide is known as a ‘triple hormone receptor agonist’. This means it mimics the actions of three hormones in the body that directly affect our ability to control hunger and our […]

Strikingly, 26% of participants on the highest dose of retatrutide (12 mg) lost more than 30% of their body weight. Losing and maintaining weight loss of more than 10% is associated with significantly reducing complications related to obesity, including hypertension, type 2 diabetes, and heart disease.

Whilst Wegovy targets GLP-1 and Mounjaro targets GLP-1 and GIP (4), neither target glucagon receptors. This means that retatrutide, with three targets, could be more effective (1). Testing has already shown that Retatrutide can help participants lose more weight in a shorter amount of time (1).

How soon will I start seeing results with Retatrutide? Most patients begin to notice reduced appetite within the first few weeks. Visible weight loss typically becomes more noticeable around weeks 4–6 and continues to improve steadily over time, especially as dosing progresses.